MPM Bioimpact LLC Buys 240,435 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

MPM Bioimpact LLC grew its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 109.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 459,943 shares of the biotechnology company's stock after purchasing an additional 240,435 shares during the quarter. MPM Bioimpact LLC owned about 1.70% of Arcturus Therapeutics worth $7,805,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARCT. Virtus ETF Advisers LLC lifted its stake in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after buying an additional 1,132 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $71,000. National Bank of Canada FI raised its stake in shares of Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock valued at $186,000 after purchasing an additional 2,036 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 3,705 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ ARCT traded up $0.01 during trading hours on Friday, hitting $11.65. 335,735 shares of the stock were exchanged, compared to its average volume of 451,393. The company has a market cap of $315.96 million, a PE ratio of -5.25 and a beta of 2.36. The company's fifty day simple moving average is $11.54 and its two-hundred day simple moving average is $15.19. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARCT has been the subject of a number of research reports. Wells Fargo & Company lowered their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research report on Monday, March 10th. Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Citigroup reissued a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of "Buy" and a consensus target price of $57.80.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.